Cargando…

A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers

The development of drug nanocarriers based on polymeric, lipid and ceramic biomaterials has been paving the way to precision medicine, where the delivery of poorly soluble active compounds and personalized doses are made possible. However, the nano-size character of these carriers has been demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales: Perugini, Valeria, Schmid, Ruth, Mørch, Ýrr, Texier, Isabelle, Brodde, Martin, Santin, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360154/
https://www.ncbi.nlm.nih.gov/pubmed/35318565
http://dx.doi.org/10.1007/s13346-022-01141-6
_version_ 1784764290316632064
author Perugini, Valeria
Schmid, Ruth
Mørch, Ýrr
Texier, Isabelle
Brodde, Martin
Santin, Matteo
author_facet Perugini, Valeria
Schmid, Ruth
Mørch, Ýrr
Texier, Isabelle
Brodde, Martin
Santin, Matteo
author_sort Perugini, Valeria
collection PubMed
description The development of drug nanocarriers based on polymeric, lipid and ceramic biomaterials has been paving the way to precision medicine, where the delivery of poorly soluble active compounds and personalized doses are made possible. However, the nano-size character of these carriers has been demonstrated to have the potential to elicit pathways of the host response different from those of the same biomaterials when engineered as larger size implants and of the drugs when administered without a carrier. Therefore, a specific regulatory framework needs to be made available that can offer robust scientific insights and provide safety data by reliable tests of these novel nano-devices. In this context, the present work presents a multistep protocol for the in vitro assessment of the hemocompatibility of nanocarriers of different physicochemical properties. Poly (ethyl butyl cyanoacrylate) nanoparticles and lipid-based (LipImage™ 815) nanoparticles of comparable hydrodynamic diameter were tested through a battery of assays using human peripheral blood samples and recapitulating the main pathways of the host response upon systemic administration; i.e., protein interactions, fibrinogen-platelet binding, cytotoxicity, and inflammatory response. The data showed the sensitivity and reproducibility of the methods adopted that were also demonstrated to determine individual variability as well as to discriminate between activation of pathways of inflammation and unintended release of inflammatory signaling caused by loss of cell integrity. Therefore, this multistep testing is proposed as a reliable protocol for nanoparticle development and emerging regulatory frameworks. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13346-022-01141-6.
format Online
Article
Text
id pubmed-9360154
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-93601542022-08-10 A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers Perugini, Valeria Schmid, Ruth Mørch, Ýrr Texier, Isabelle Brodde, Martin Santin, Matteo Drug Deliv Transl Res Original Article The development of drug nanocarriers based on polymeric, lipid and ceramic biomaterials has been paving the way to precision medicine, where the delivery of poorly soluble active compounds and personalized doses are made possible. However, the nano-size character of these carriers has been demonstrated to have the potential to elicit pathways of the host response different from those of the same biomaterials when engineered as larger size implants and of the drugs when administered without a carrier. Therefore, a specific regulatory framework needs to be made available that can offer robust scientific insights and provide safety data by reliable tests of these novel nano-devices. In this context, the present work presents a multistep protocol for the in vitro assessment of the hemocompatibility of nanocarriers of different physicochemical properties. Poly (ethyl butyl cyanoacrylate) nanoparticles and lipid-based (LipImage™ 815) nanoparticles of comparable hydrodynamic diameter were tested through a battery of assays using human peripheral blood samples and recapitulating the main pathways of the host response upon systemic administration; i.e., protein interactions, fibrinogen-platelet binding, cytotoxicity, and inflammatory response. The data showed the sensitivity and reproducibility of the methods adopted that were also demonstrated to determine individual variability as well as to discriminate between activation of pathways of inflammation and unintended release of inflammatory signaling caused by loss of cell integrity. Therefore, this multistep testing is proposed as a reliable protocol for nanoparticle development and emerging regulatory frameworks. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13346-022-01141-6. Springer US 2022-03-22 2022 /pmc/articles/PMC9360154/ /pubmed/35318565 http://dx.doi.org/10.1007/s13346-022-01141-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Perugini, Valeria
Schmid, Ruth
Mørch, Ýrr
Texier, Isabelle
Brodde, Martin
Santin, Matteo
A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers
title A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers
title_full A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers
title_fullStr A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers
title_full_unstemmed A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers
title_short A multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers
title_sort multistep in vitro hemocompatibility testing protocol recapitulating the foreign body reaction to nanocarriers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360154/
https://www.ncbi.nlm.nih.gov/pubmed/35318565
http://dx.doi.org/10.1007/s13346-022-01141-6
work_keys_str_mv AT peruginivaleria amultistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT schmidruth amultistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT mørchyrr amultistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT texierisabelle amultistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT broddemartin amultistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT santinmatteo amultistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT peruginivaleria multistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT schmidruth multistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT mørchyrr multistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT texierisabelle multistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT broddemartin multistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers
AT santinmatteo multistepinvitrohemocompatibilitytestingprotocolrecapitulatingtheforeignbodyreactiontonanocarriers